Current state and progress of intravitreal injection of chemotherapeutic agents for the treatment of vitreoretinal lymphoma
10.3760/cma.j.cn511434-20200826-00414
- VernacularTitle:玻璃体腔注射化学药物治疗玻璃体视网膜淋巴瘤的研究现状与进展
- Author:
Chuanzhen ZHENG
1
;
Xinjun REN
;
Xiaomin ZHANG
Author Information
1. 天津医科大学眼科医院、眼视光学院、眼科研究所 天津市视网膜功能与疾病重点实验室 天津市眼科学与视觉科学国际联合研究中心 300384
- Keywords:
Lymphoma;
non-Hodgkin;
Methotrexate;
Review
- From:
Chinese Journal of Ocular Fundus Diseases
2021;37(9):731-736
- CountryChina
- Language:Chinese
-
Abstract:
Primary vitreoretinal lymphoma (PVRL) is one of the most common type of primary intraocular lymphoma. The current treatment options include local ocular radiotherapy (radiotherapy), systemic chemotherapy (chemotherapy), local ocular chemotherapy, and combination therapy. The treatment options are different at different stages of PVRL, however, there is no uniform treatment guideline. Local ocular chemotherapy can make the drug reach effective therapeutic concentration in the eye, and it can be repeated many times. At the same time, it can avoid the adverse reactions caused by systemic medication or radiotherapy. It is an ideal choice for relieving ocular symptoms. At present, the mainstream ocular local chemotherapeutics are methotrexate (MTX) and rituximab (RTX). The basic consensus about the intravitreal injection of MTX (IVM) is the induction-consolidation-maintenance model, however, the time of each stage and frequency of IVM are diverse. The time interval of intravitreal injection of RTX is also variable, ranging from 1 time/week to 1 time/months and so on. Corneal epithelial lesions caused by frequent MTX injections and the higher recurrence rate after RTX treatment are the main reasons for changing the treatment plan. For patients with primary central nervous system lymphoma and PVRL, combined treatment with neurology department is necessary to save patient's lives, ophthalmology treatment relieves ocular symptoms and improves the patient's quality of life. For patients with PVRL alone without central nervous system involvement, ophthalmology treatment is necessary to control patient's eye symptoms, and close follow-up should be followed to find the involvement of the central nervous system in time, and then combined with neurological treatment to save patient’s lives.
